Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2017

Barnet Megan B, O'Toole Sandra, Horvath Lisa G, Selinger Christina, Yu Bing, Ng Chiu Chin, Boyer Michael, Cooper Wendy A, Kao Steven

Abstract excerpt

OBJECTIVES: The evolution of EGFR tyrosine kinase inhibitors (TKIs) has changed the landscape of disease for a subset of patients with NSCLC. Most patients with an EGFR mutation respond to these drugs; however, a proportion show limited or no tumor response. We explored the impact of co-mutation (double or multiple mutation), compared with a single mutation, of the EGFR gene on response to TKIs in a series of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 27639677
DOI: 10.1016/j.jtho.2016.09.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.PMID 27639677Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Real-world efficacy of first- and second-generation EGFR TKIs in NSCLC with EGFR co-mutations: a Vietnamese cohort study.Semantic proximity Read ↗

Real-World Efficacy of First- and Second-Generation EGFR TKIs in NSCLC with EGFR Co-mutations: A Vietnamese Cohort StudySemantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

EGFR G719X + S768I co-mutations in NSCLC: genomic landscape and differential responses to EGFR-TKIs in a large real-world cohort.Semantic proximity Read ↗

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.Semantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).Semantic proximity Read ↗

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.